Wisp and Visby Medical’s new partnership adds same-day care to at-home sexual health testing

Sexual health is part of your health, but the infrastructure around it has rarely made it easy to act on. When it comes to common bacterial infections like chlamydia and gonorrhea, testing is the only reliable way to know your status. For most people, that has meant a clinic visit, a lab order, and results days later. Visby Medical built a palm-sized PCR device that runs the full test at home in 30 minutes. Through a new partnership with Wisp, a positive result connects directly to same-day prescribing.

What it is

Visby’s device is single-use and runs entirely in your hands. You collect a vaginal swab, add the sample to the device, and results appear in the Visby app within 30 minutes. The test screens for chlamydia, gonorrhea, and trichomoniasis—three of the most common curable STIs.

PCR, or polymerase chain reaction, is the same technology clinical labs use: it works by amplifying trace amounts of genetic material in a sample until there’s enough to detect. Most at-home sexual health tests still require mailing a sample to a lab to run that analysis, which is where the multi-day wait comes from. Visby’s device runs the full process in your hands, which is what makes the 30-minute turnaround possible.

Visby’s at-home STI test.

Where Wisp comes in

Wisp operates across all 50 states with no-appointment telehealth and same-day prescribing, and has served over 1.8 million patients. Through this partnership, a positive result connects directly to a Wisp provider who can prescribe treatment the same day. A result is only as useful as what comes next, and now, patients may be able to start treatment sooner and get relief quicker.

Why it matters

All three infections are frequently asymptomatic, so most people who have one won’t know it. Left undetected, chlamydia and gonorrhea can progress to pelvic inflammatory disease, chronic pelvic pain, and in some cases, fertility issues or reproductive damage. Trichomoniasis, while rarely serious on its own, increases susceptibility to other infections. According to the brand, the Visby device’s accuracy holds up clinically: in a multi-site study of more than 2,000 participants, it correctly identified over 97% of positive chlamydia cases, 100% of positive gonorrhea cases, and nearly 98% of positive trichomoniasis cases.